Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty six Aquestive Therapeutics Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, we'll open up for questions. Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, Faith Pomeroy Ward. Please go ahead. Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer and Ernie Toth, Chief Financial Officer, who are going to provide an overview of the company's reported financial results for the first quarter ended 03/31/2026, and a progress update on the company's key 2026 objectives, followed by a Q and A session. During the Q and A session, the team will be joined by Doctor. Matt Greenhaut, Chief Medical Officer, Molina Chaffee, Senior Vice President, Regulatory Affairs, Sherri Korchinski, Chief Commercial Officer and Doctor. Matthew Davis, Chief Development Officer. As a reminder, the company's remarks today correspond with the earnings release that was issued after market closed yesterday. In addition, a recording of today's call and related supplemental materials will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call. To remind you, the Aquestive team will be discussing some non GAAP financial measures this morning as part of its review of first quarter twenty twenty six results. A description of these measures along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website. During the call, the company will be making forward looking statements....